Noelle V. Frey

Hospital of the University of Pennsylvania — United States

Medicine · Health Sciences

53h-index22.7kcitations451works8.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(253), Hematopoietic Stem Cell Transplantation(72), Acute Lymphoblastic Leukemia research(62), Acute Myeloid Leukemia Research(61), Immune Cell Function and Interaction(47)

Publications450 total

Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
Blood Immunology & Cellular Therapy·2025Open Access
Figure S11 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S6 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S4 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S8 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S9 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S2 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S3 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Table S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S7 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S5 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S10 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
Figure S1 from Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
2025Open Access
IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia
Blood·2025Open Access
Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab
Blood·2025
Cytotoxic, natural killer-like ex-tissue resident memory T-cells circulate in human chronic graft-versus-host disease at diagnosis
Blood·2025Open Access
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Blood Advances·2025· 1 citedOpen Access
Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome><[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>
Transplantation and Cellular Therapy·2025Open Access
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
New England Journal of Medicine·2025· 59 cited
page 1 of 23Next →

Frequent Co-authors

David L. Porter(26), Carl H. June(25), Simon F. Lacey(19), Stephan A. Grupp(18), J. Joseph Melenhorst(17), Saar Gill(17), Bruce L. Levine(14), Elizabeth O. Hexner(14), Shannon L. Maude(13), Selina M. Luger(13), Alison W. Loren(11), Wei‐Ting Hwang(9), Sunita D. Nasta(9), Stephen J. Schuster(9), Edward A. Stadtmauer(9), David T. Teachey(8), David Porter(8), Edward Pequignot(8), Pamela A. Shaw(7), Joseph A. Fraietta(7)